Therapeutic Drug Monitoring for HIV

Overview | Research

Overview

Drug Level Testing (April 24, 2012)
To read PDF, click here.
From AIDS InfoNet
Therapeutic Drug Monitoring, or Integrating Antiretroviral Pharmacokinetics, HIV Resistance, and Genetics (July 2003)
[Archived Article]
Highlights from the IAPAC Sessions 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Therapeutic Drug Monitoring: The Next Best Thing in HIV Treatment? (Fall 2002)
[Archived Article]
To read PDF, click here.
In STEP Perspective, from Seattle Treatment Education Project
Pharmacology: Drug Level Monitoring and Beyond (July 2001)
[Archived Article]
To read PDF, click here.
From Project Inform
The Ups and Downs of Drug Levels: A Pharmacokinetics Primer (July/August 2001)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
The Ups and Downs of Drug Levels (May/June 2001)
[Archived Article]
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Therapeutic Drug Monitoring: Medscape Web Resource Page (March 30, 2001)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Editorial: Putting an End to the Guesswork (February 2001)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Optimal Medical Management: Entering the Era of Truly Individualized Antiretroviral Therapy (February 2001)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Optimal Medical Management: Clinical Considerations in Therapeutic Drug Monitoring (February 2001)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Therapeutic Drug Monitoring (Autumn 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Some Unanswered Questions About Therapeutic Drug Monitoring (July 2000)
[Archived Article]
In TAGline, from Treatment Action Group

Research

Canadian Researchers Develop Portable Device to Monitor HIV in Rural Areas (December 13, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
Africa HIV City Care Questioned (July 21, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
Hair Samples Can Be Used to Measure Effectiveness of Antiretrovirals, Researchers Say (March 17, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
Using Hair to Manage HIV/AIDS and Predict Treatment Success (March 3, 2009)
From University of California-San Francisco
On TheBodyPRO.com
Drug Level Monitoring Nearly Doubles Likelihood of Reaching Target Levels (December 17, 2007)
From aidsmap.com
Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Wide Variability in Drug Levels Casts Doubt on the Practicality of Therapeutic Drug Monitoring (March 28, 2006)
From aidsmap.com
New Research Explores Potential Value of Therapeutic Drug Monitoring (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Drug Monitoring and Pharmacology: More Mixes Nixed By Concentration Preoccupations (August 2004)
[Archived Article]
Highlights from a CROI 2004 post-conference workshop on drug-drug interactions.
In TAGline, from Treatment Action Group
On TheBodyPRO.com
Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
[Archived Article]
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
To Measure or Not to Measure Drug Levels -- That Is the Question (March/April 2004)
[Archived Article]
Through the use of therapeutic drug monitoring, researchers are able to adjust patients' drug levels and reduce toxicity.
In Positively Aware, from Test Positive Aware Network
Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Importance of Resistance Testing and Therapeutic Drug Monitoring for Treatment Success (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
[Archived Article]
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Plasma Protease Inhibitor Levels Can Mark Nonadherence (January 23, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
Therapeutic Drug Monitoring: Does It Make a Difference? (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from TheBodyPRO.com
Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
Hair Sample May Give Clues to HIV Drug Response (October 16, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from TheBodyPRO.com
The Role of Therapeutic Drug Level Monitoring in Clinical Practice (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy? (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
Therapeutic Drug Monitoring: A Must for Clinical Practice? (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
Therapeutic Drug Monitoring (Summer/Autumn 2001)
[Archived Article]
Report on the 2nd International Workshop on Clinical Pharmacology in HIV Therapy.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Usefulness of Protease Inhibitor Therapeutic Drug Monitoring? PharmAdapt: A Prospective Multicentric Randomized Controlled Trial -- 12-Week Results (February 4, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Therapeutic Drug Monitoring in HIV Clinical Care (July 2000)
[Archived Article]
A report from the First International Workshop on Pharmacology in HIV Therapy.
In TAGline, from Treatment Action Group